These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 19043297)

  • 1. Pharmacoeconomic analysis of hypertriglyceridemia treatment at medical institutions.
    Takahashi T; Saegusa Y; Takimoto Y; Shiragami M
    Yakugaku Zasshi; 2008 Dec; 128(12):1783-9. PubMed ID: 19043297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of statins in hypertriglyceridemia.
    Stein EA; Lane M; Laskarzewski P
    Am J Cardiol; 1998 Feb; 81(4A):66B-69B. PubMed ID: 9526817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of increasing doses of atorvastatin on the atherogenic lipid subclasses commonly associated with hypertriglyceridemia.
    Karalis DG; Ishisaka DY; Luo D; Ntanios F; Wun CC
    Am J Cardiol; 2007 Aug; 100(3):445-9. PubMed ID: 17659926
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia.
    Bakker-Arkema RG; Davidson MH; Goldstein RJ; Davignon J; Isaacsohn JL; Weiss SR; Keilson LM; Brown WV; Miller VT; Shurzinske LJ; Black DM
    JAMA; 1996 Jan; 275(2):128-33. PubMed ID: 8531308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacoeconomic evaluation of anti-hyperlipidemic agent fenofibrate.
    Hayakawa T; Shimoyama K; Sekiya S; Sekiguchi M; Inotsume N
    Yakugaku Zasshi; 2002 Dec; 122(12):1145-51. PubMed ID: 12510391
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of atorvastatin when not administered daily.
    Ghattas AE; Pimenta J
    Arq Bras Cardiol; 2007 Nov; 89(5):294-300, 325-32. PubMed ID: 18066453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.
    Frost RJ; Otto C; Geiss HC; Schwandt P; Parhofer KG
    Am J Cardiol; 2001 Jan; 87(1):44-8. PubMed ID: 11137832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High-dose atorvastatin therapy in severe heterozygous familial hypercholesterolaemia.
    Wierzbicki AS; Lumb PJ; Semra YK; Crook MA
    QJM; 1998 Apr; 91(4):291-4. PubMed ID: 9666952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Atorvastatin: an updated review of its pharmacological properties and use in dyslipidaemia.
    Malhotra HS; Goa KL
    Drugs; 2001; 61(12):1835-81. PubMed ID: 11693468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.
    Liamis G; Kakafika A; Bairaktari E; Miltiadous G; Tsimihodimos V; Goudevenos J; Achimastos A; Elisaf M
    Curr Med Res Opin; 2002; 18(3):125-8. PubMed ID: 12094821
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
    Schwartz GG; Ganz P; Waters D; Arikian S
    Am J Cardiol; 2003 Nov; 92(9):1109-12. PubMed ID: 14583367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lipid-lowering activity of atorvastatin and lovastatin in rodent species: triglyceride-lowering in rats correlates with efficacy in LDL animal models.
    Krause BR; Newton RS
    Atherosclerosis; 1995 Oct; 117(2):237-44. PubMed ID: 8801869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rosuvastatin is cost-effective compared with atorvastatin in reaching cholesterol goals.
    Hirsch M; O'donnell J; Olsson A
    Int J Cardiol; 2005 Oct; 104(3):251-6. PubMed ID: 16186052
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A model for assessing the cost-effectiveness of atorvastatin and simvastatin in achieving Canadian low-density lipoprotein cholesterol targets.
    Lachaine J; Merikle E; Tarride JE; Montpetit M; Rinfret S
    Clin Ther; 2007 Mar; 29(3):519-28. PubMed ID: 17577472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of combination of atorvastatin and micronised fenofibrate in the treatment of severe mixed hyperlipidemia.
    Kiortisis DN; Millionis H; Bairaktari E; Elisaf MS
    Eur J Clin Pharmacol; 2000 Dec; 56(9-10):631-5. PubMed ID: 11214768
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of a new HMG-CoA reductase inhibitor, atorvastatin, on lipids, apolipoproteins and lipoprotein particles in patients with elevated serum cholesterol and triglyceride levels.
    Alaupovic P; Heinonen T; Shurzinske L; Black DM
    Atherosclerosis; 1997 Aug; 133(1):123-33. PubMed ID: 9258416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.
    Koh KK; Quon MJ; Han SH; Chung WJ; Ahn JY; Seo YH; Choi IS; Shin EK
    J Am Coll Cardiol; 2005 May; 45(10):1649-53. PubMed ID: 15893182
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial).
    Grundy SM; Vega GL; Tomassini JE; Tershakovec AM
    Am J Cardiol; 2011 Jul; 108(1):40-6. PubMed ID: 21565322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of alternate day therapy with atorvastatin and fenofibrate combination in mixed dyslipidemia: a randomized controlled trial.
    Harivenkatesh N; David DC; Haribalaji N; Sudhakar MK
    J Cardiovasc Pharmacol Ther; 2014 May; 19(3):296-303. PubMed ID: 24516261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.